IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
25 nov. 2024 07h00 HE
|
IN8bio, Inc
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
12 nov. 2024 16h26 HE
|
IN8bio, Inc
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
12 nov. 2024 07h00 HE
|
IN8bio, Inc
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
05 nov. 2024 09h00 HE
|
IN8bio, Inc
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
IN8bio Announces Pricing of $12.4 Million Private Placement
01 oct. 2024 08h00 HE
|
IN8bio, Inc
IN8bio Announces Pricing of $12.4 Million Private Placement
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
04 sept. 2024 16h01 HE
|
IN8bio, Inc
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
29 août 2024 06h05 HE
|
IN8bio, Inc
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
12 août 2024 08h05 HE
|
IN8bio, Inc
IN8bio Announces FDA Guidance for Registrational Trial of INB-100 as 100% of AML Patients remain in Complete Remission
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
08 août 2024 16h05 HE
|
IN8bio, Inc
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
24 juin 2024 08h00 HE
|
IN8bio, Inc
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that...